Cardiac Rehabilitation in Congenital Heart Disease: Effects on Brain and Cognitive Functions
Launched by MONTREAL HEART INSTITUTE · Jan 13, 2022
Trial Information
Current as of July 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Thanks to advances in medical research, individuals born with heart defects (Congenital Heart Disease: CHD), are now 95% more likely to reach adulthood, with around 250,000 adults with CHD currently living in Canada. CHD-related diseases and conditions are extremely common in the adult CHD population, and undermine the successes achieved by medical research. For example, compared to healthy peers, adults with CHD are between 3 to 6 times more likely to experience heart accidents or develop other heart conditions during lifetime. Adults with CHD also have more health problems, and have betwe...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • being able to read, understand and sign the information and consent form;
- • being aged 18 or more at the time of consent;
- • having a diagnosis of congenital heart disease with moderate or severe risk;
- • being referred to the EPIC center in cardiovascular rehabilitation;
- • being able to perform a maximal cardiopulmonary stress test and an exercise training program in accordance with current recommendations for cardiovascular rehabilitation;
- • having Internet access.
- Exclusion Criteria:
- • recent major cardiovascular events or interventions \<3 months;
- • uncontrolled mental or psychiatric disorder in the last 6 months;
- • genetic syndromes affecting cognition;
- • excessive alcohol consumption (\> 15 drinks / week);
- • current participation in other clinical trials;
- • contraindication to stress testing and / or physical training;
- • severe intolerance to physical exercise.
About Montreal Heart Institute
The Montreal Heart Institute (MHI) is a leading academic research center dedicated to advancing the field of cardiology through innovative clinical trials and groundbreaking medical research. Renowned for its commitment to improving patient care, MHI integrates clinical practice with cutting-edge research, fostering collaboration among healthcare professionals, scientists, and industry partners. The institute focuses on a wide range of cardiovascular conditions, aiming to develop and evaluate new therapies and interventions that enhance outcomes for patients with heart disease. With a strong emphasis on ethical standards and patient safety, the Montreal Heart Institute is at the forefront of cardiovascular research, contributing significantly to the global advancement of heart health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montréal, Quebec, Canada
Patients applied
Trial Officials
Louis Bherer, PhD
Principal Investigator
EPIC Center of the Montreal Heart Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials